Your browser doesn't support javascript.
loading
HTCC as a highly effective polymeric inhibitor of SARS-CoV-2 and MERS-CoV
Aleksandra Milewska; Ying Chi; Artur Szczepanski; Emilia Barreto-Duran; Kevin Liu; Dan Liu; Xiling Guo; Yiyue Ge; Jingxin Li; Lunbiao Cui; Marek Ochman; Maciej Urlik; Sylwia Rodziewicz-Motowidlo; Fengcai Zhu; Krzysztof Szczubialka; Maria Nowakowska; Krzysztof Pyrc.
Afiliação
  • Aleksandra Milewska; Virogenetics Laboratory of Virology, Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387 Krakow, Poland.
  • Ying Chi; NHC Key Lab of Enteric Pathogenic Microbiology, Jiangsu Provincial Centre for Disease Control & Prevention. 172 Jiangsu Rd., Nanjing, Jiangsu, 210009, PR China
  • Artur Szczepanski; Microbiology Department, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387 Krakow, Poland.
  • Emilia Barreto-Duran; Virogenetics Laboratory of Virology, Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387 Krakow, Poland.
  • Kevin Liu; Nanjing Techboon Institute of Clinical Medicine. #1003, Tower B of Yangtze Sci. & Tech. Innovation Centre, 211 Pubing Rd., Nanjing, Jiangsu, 211800, PR China.
  • Dan Liu; Nanjing Techboon Institute of Clinical Medicine. #1003, Tower B of Yangtze Sci. & Tech. Innovation Centre, 211 Pubing Rd., Nanjing, Jiangsu, 211800, PR China.
  • Xiling Guo; NHC Key Lab of Enteric Pathogenic Microbiology, Jiangsu Provincial Centre for Disease Control & Prevention. 172 Jiangsu Rd., Nanjing, Jiangsu, 210009, PR China
  • Yiyue Ge; NHC Key Lab of Enteric Pathogenic Microbiology, Jiangsu Provincial Centre for Disease Control & Prevention. 172 Jiangsu Rd., Nanjing, Jiangsu, 210009, PR China
  • Jingxin Li; NHC Key Lab of Enteric Pathogenic Microbiology, Jiangsu Provincial Centre for Disease Control & Prevention. 172 Jiangsu Rd., Nanjing, Jiangsu, 210009, PR China
  • Lunbiao Cui; NHC Key Lab of Enteric Pathogenic Microbiology, Jiangsu Provincial Centre for Disease Control & Prevention. 172 Jiangsu Rd., Nanjing, Jiangsu, 210009, PR China
  • Marek Ochman; Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Medical University of Silesia in Katowice, Silesian Centre for Heart Diseases, Zab
  • Maciej Urlik; Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Medical University of Silesia in Katowice, Silesian Centre for Heart Diseases, Zab
  • Sylwia Rodziewicz-Motowidlo; Department of Biomedical Chemistry, Faculty of Chemistry, University of Gdansk, Wita Stwosza 63, 80-308 Gdansk, Poland.
  • Fengcai Zhu; Centre for Global Health, Nanjing Medical University. 18 Tianyuan Rd. E., Nanjing, Jiangsu, 210009, PR China
  • Krzysztof Szczubialka; Department of Physical Chemistry, Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387, Krakow, Poland.
  • Maria Nowakowska; Department of Physical Chemistry, Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387, Krakow, Poland.
  • Krzysztof Pyrc; Virogenetics Laboratory of Virology, Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387 Krakow, Poland.
Preprint em Inglês | bioRxiv | ID: ppbiorxiv-014183
ABSTRACT
The beginning of 2020 brought us information about the novel coronavirus emerging in China. Rapid research resulted in the characterization of the pathogen, which appeared to be a member of the SARS-like cluster, commonly seen in bats. Despite the global and local efforts, the virus escaped the healthcare measures and rapidly spread in China and later globally, officially causing a pandemic and global crisis in March 2020. At present, different scenarios are being written to contain the virus, but the development of novel anticoronavirals for all highly pathogenic coronaviruses remains the major challenge. Here, we describe the antiviral activity of previously developed by us HTCC compound (N-(2-hydroxypropyl)-3-trimethylammonium chitosan chloride), which may be used as potential inhibitor of currently circulating highly pathogenic coronaviruses - SARS-CoV-2 and MERS-CoV.
Licença
cc_no
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Tipo de estudo: Experimental_studies Idioma: Inglês Ano de publicação: 2020 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Tipo de estudo: Experimental_studies Idioma: Inglês Ano de publicação: 2020 Tipo de documento: Preprint
...